Serum Resistin and Adiponectin Levels in Relation with Metabolic Changes in PCO Patients
Keywords:
Polycystic ovary, Resistin, AdiponectinAbstract
Background:With a 5%–10% global incidence rate, polycystic ovarian syndrome (PCOS) is one of the
most prevalent endocrinal illnesses affecting premenopausal women. Understanding the
pathophysiology of the condition and how to treat it by inhibiting or controlling
associated pathways may need research into the inflammatory processes and mediators
that contribute to the onset and progression of PCOS.
Aim of study:
The current study aims to determine the relationship between serum levels of resistin and
adiponectin and metabolic alterations in PCO patients.
Methods:
Fasting blood samples were collected from 100 PCO married infertile women
(23.30±4.66 years) attending Bint AL-Hoda and Al-Shatra hospitals in Thi- Qar province
- Iraq, in addition to 50 healthy age matched (23.84±4.80 years) control.
According to BMI and fasting serum glucose level, the patients of PCO were classified
into four groups: normal weight nondiabetic patients, normal weight diabetic patients,
overweight non-diabetic patients and overweight diabetic patients compared with
healthy control.
Results:
Adiponectin considerably decreased in all PCO subgroups compared to healthy controls,
but resistin significantly rose in all PCO patients. However, its level was more
substantially (P˂0.05) elevated in overweight diabetics. All PCOS patients had
significantly higher levels of triglycerides, total cholesterol, LDL, and VLDL as
compared to healthy controls. While HDL was not significantly changed in all subgroups
of PCO patients except it significantly declined in overweight diabetic PCO patients.
Conclusion:
PCOS patients had dramatically changed adiponectin, or resistin levels compared to
healthy women. PCOS patients showed low adiponectin levels and high serum resistin
levels, indicating that the pathophysiology of PCOS may be influenced by serum
adiponectin levels. However, in PCOS patients, resistin levels had a separate relationship
with insulin resistance and BMI.
References
- lexander CJ, Tangchitnob EP, Lepor NE. Polycystic ovary syndrome: a major
unrecognized cardiovascular risk factor in women. Rev Cardiovasc Med 2009;10(2):83-
- Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J
Clin Endocrinol Metab 1961;21:1440-1447.
- Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, et al. Consensus on women's
health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRMSponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012;97(1):28-38.e25.
- Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, et al. Androgen Excess
Society. Positions statement: criteria for defining polycystic ovary syndrome as a
predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin
Endocrinol Metab 2006;91(11):4237-4245.
- Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition
with psychological, reproductive and metabolic manifestations that impacts on health
across the lifespan. BMC Med 2010;8:41.
- Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary
syndrome revisited: an update on mechanisms and implications. Endocr Rev
;33(6):981-1030.
- Randeva HS, Tan BK, Weickert MO, Lois K, et al. Cardiometabolic aspects of
the polycystic ovary syndrome. Endocr Rev 2012;33(5):812-841.
- Carmina E, Bucchieri S, Esposito A, Del Puente A, et al. Abdominal fat quantity
and distribution in women with polycystic ovary syndrome and extent of its relation to
insulin resistance. J Clin Endocrinol Metab 2007;92(7):2500-2505.
- Hotta K, Funahashi T, Arita Y, Takahashi M, et al. Plasma concentrations of a
novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler
Thromb Vasc Biol 2000;20(6):1595-1599.
- Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, et al. Adiponectin: a key
adipocytokine in metabolic syndrome. Clin Sci (Lond). 2006;110(3):267-278.
- Ouchi N, Kihara S, Arita Y, Maeda K, et al. Novel modulator for endothelial
adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation
;100(25):2473-2476.
- Ardawi MS, Rouzi AA. Plasma adiponectin and insulin resistance in women with
polycystic ovary syndrome. Fertil Steril 2005;83(6):1708-1716.
- Carmina E, Orio F, Palomba S, Cascella T, et al. Evidence for altered adipocyte
function in polycystic ovary syndrome. Eur J Endocrinol 2005;152(3):389-394.
- Lazaridou S, Dinas K, Tziomalos K. Prevalence, pathogenesis and management
of prediabetes and type 2 diabetes mellitus in patients with polycystic ovary syndrome.
Hormones (Athens) 2017;16(4):373-380.
- Lazaridou S, Dinas K, Tziomalos K. Prevalence, pathogenesis and management
of prediabetes and type 2 diabetes mellitus in patients with polycystic ovary syndrome.
Hormones (Athens) 2017;16(4):373-380.
- Weyer C, Funahashi T, Tanaka S, Hotta K, et al. Hypoadiponectinemia in obesity
and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin
Endocrinol Metab 2001;86(5):1930-1935.
- Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Alvarez-Blasco F, et al.
Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study.
Hum Reprod 2006;21(9):2257-65.
- Nishizawa H, Shimomura I, Kishida K, Maeda N, et al. Androgens decrease
plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes
;51(9):2734-2741.
- Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin
concentrations in women with dyslipidemia. J Clin Endocrinol Metab 2002;87(6):2764-
- Ukkola O, Santaniemi M. Adiponectin: a link between excess adiposity and
associated comorbidities? J Mol Med (Berl) 2002;80(11):696-702.
- Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance.
Trends Endocrinol Metab. 2002;13(1):18-23.
- Steppan CM, Bailey ST, Bhat S, Brown EJ, et al. The hormone resistin links
obesity to diabetes. Nature 2001;409(6818):307-312.
- Panidis D, Koliakos G, Kourtis A, Farmakiotis D, et al. Serum resistin levels in
women with polycystic ovary syndrome. Fertil Steril 2004;81(2):361-366.
- Xita N, Georgiou I, Tsatsoulis A, Kourtis A, et al. A polymorphism in the resistin
gene promoter is associated with body mass index in women with polycystic ovary
syndrome. Fertil Steril 2004 N;82(5):1466-1467.
- Seow KM, Juan CC, Wu LY, Hsu YP, et al. Serum and adipocyte resistin in
polycystic ovary syndrome with insulin resistance. Hum Reprod 2004;19(1):48-53.
- Kim KH, Lee K, Moon YS, Sul HS. A cysteine-rich adipose tissue-specific
secretory factor inhibits adipocyte differentiation. J Biol Chem 2001;276(14):11252-
- Carmina E, Orio F, Palomba S, Longo RA, et al. Endothelial dysfunction in
PCOS: role of obesity and adipose hormones. Am J Med 2006;119(4):356.
- Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP.
Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab
;18(7):280-285.
- Wild RA, Painter PC, Coulson PB, Carruth KB, et al. Lipoprotein lipid
concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin
Endocrinol Metab 1985;61(5):946-951.
- Wild RA, Painter PC, Coulson PB, Carruth KB, et al. Lipoprotein lipid
concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin
Endocrinol Metab 1985;61(5):946-951.
- Bik W, Baranowska-Bik A, Wolinska-Witort E, Chmielowska M, et al. The
relationship between metabolic status and levels of adiponectin and ghrelin in lean
women with polycystic ovary syndrome. Gynecol Endocrinol 2007;23(6):325-31.
- Komatsu M, Ohfusa H, Aizawa T, Hashizume K. Adiponectin inversely correlates
with high sensitive C-reactive protein and triglycerides, but not with insulin sensitivity, in
apparently healthy Japanese men. Endocr J 2007;54(4):553-558.
- Koh KK, Quon MJ, Han SH, Lee Y, et al. Simvastatin improves flow-mediated
dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic
patients. Diabetes Care 2008;31(4):776-782
Downloads
Published
Issue
Section
License
Copyright (c) 2024 University of Thi-Qar Journal Of Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
